Retrospective evaluation of the efficacy of CDK4/6 inhibitors compared to ER and PR levels in hormone receptor positive HER2 negative metastatic breast cancer patient DOI Creative Commons
Esma Uguztemur, Derya Kıvrak Salim, Banu Öztürk

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Дек. 11, 2024

Abstract CDK4/6 inhibitors with aromatase as the first-line standard-of-care in hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2)- negative advanced breast cancer. Phase III studies examining have not identified significant predictive or prognostic markers.In this study, we aimed to restrospectively evaluate efficacy of according ER and PR levels HR+, HER2 (-) metastatic Methods 171 patients were evaluated retrospectively. Patients divided into 2 groups level ≥90 (n=119) <90 (n=52). Demographic characteristics, histopathologic findings, menopausal status, presence visceral metastases, treatment response side effects both groups. Results The mean age was 55 years, 75% postmenopausal 67% denova metastatic. Visceral metastases present 73% patients, 53% had received second line beyond. 87% clinical benefit, 12% primary non-responders. ER<90 younger, higher grade (p=0.018), more liver (p=0.009),reached therapy later, shorter follow-up. Duration response(DOR ) statistically longer those who (21.3 months vs. 11 months, p=0.034). In ER≥90 group, OS reached independently line, while group 30 second-line group. time until inhibitor associated (NR-33.9 p=0.019) no impact status on overall survival. Median PFS 50 statistical differences based levels. Receiving later significantly shortened PFS. Conclusions it observed that receiving inhibitor. However, initiation impacted PFS, being aggressive disease.

Язык: Английский

Retrospective evaluation of the efficacy of CDK4/6 inhibitors compared to ER and PR levels in hormone receptor positive HER2 negative metastatic breast cancer patient DOI Creative Commons
Esma Uguztemur, Derya Kıvrak Salim, Banu Öztürk

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Дек. 11, 2024

Abstract CDK4/6 inhibitors with aromatase as the first-line standard-of-care in hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2)- negative advanced breast cancer. Phase III studies examining have not identified significant predictive or prognostic markers.In this study, we aimed to restrospectively evaluate efficacy of according ER and PR levels HR+, HER2 (-) metastatic Methods 171 patients were evaluated retrospectively. Patients divided into 2 groups level ≥90 (n=119) <90 (n=52). Demographic characteristics, histopathologic findings, menopausal status, presence visceral metastases, treatment response side effects both groups. Results The mean age was 55 years, 75% postmenopausal 67% denova metastatic. Visceral metastases present 73% patients, 53% had received second line beyond. 87% clinical benefit, 12% primary non-responders. ER<90 younger, higher grade (p=0.018), more liver (p=0.009),reached therapy later, shorter follow-up. Duration response(DOR ) statistically longer those who (21.3 months vs. 11 months, p=0.034). In ER≥90 group, OS reached independently line, while group 30 second-line group. time until inhibitor associated (NR-33.9 p=0.019) no impact status on overall survival. Median PFS 50 statistical differences based levels. Receiving later significantly shortened PFS. Conclusions it observed that receiving inhibitor. However, initiation impacted PFS, being aggressive disease.

Язык: Английский

Процитировано

0